Paul B Watkins

UNCCH, School of Medicine, Medicine

• Home
• Expert Overview
• Profile
• Publications
• Grants
• Patents
• Similar Experts
• Journals
• Trends
• Institutional Network
• Coauthor Network
• Research Network
• Curriculum Vitae

Paul B Watkins

• Organizations
  University of North Carolina at Chapel Hill
  
  School of Medicine
  
  Medicine
  
  

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

  Select All    |   Export

• 1.

  2013

  LaToya M. Griffin; Paul B. Watkins; Cassandra H. Perry; Robert L. St. Claire III; Kim L. R. Brouwer

  Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes

  Drug Metabolism and Disposition. 2013;41(1):188-196.
  1

• 2.

  2013

  Rex E. Jeffries; Michael P. Gamcsik; Kayvan R. Keshari; Peter Pediaditakis; Andrey P. Tikunov; Gregory B. Young; Haakil Lee; Paul B. Watkins; Jeffrey M. MacDonald

  Effect of oxygen concentration on viability and metabolism in a fluidized-bed bioartificial liver using ³¹P and ¹³C NMR spectroscopy

  Tissue Engineering - Part C: Methods. 2013;19(2):93-100.
  0

• 3.

  2012

  Sudin Bhattacharya; Lisl K.M. Shoda; Qiang Zhang; Courtney G. Woods; Brett A. Howell; Scott Q. Siler; Jeffrey L. Woodhead; Yuching Yang; Patrick McMullen; Paul B. Watkins; et al.

  Modeling drug-and chemical-induced hepatotoxicity with systems biology approaches

  Frontiers in Neurology. 2012;3 DEC.
  0

• 4.

  2012

  Liwen Zhang; Pierre R. Bushel; Jeff Chou; Zhou Tong; Paul B. Watkins

  Identification of identical transcript changes in liver and whole blood during acetaminophen toxicity

  Frontiers in Genetics. 2012;3(SEP).
  0

• 5.

  2012

  Jason H. Winnike; Peter Pediaditakis; Justyna E. Wolak; Randall E. McClelland; Paul B. Watkins; Jeffrey M. Macdonald

  Stable isotope resolved metabolomics of primary human hepatocytes reveals a stressed phenotype

  Metabolomics. 2012;8(1):34-49.
  2

• 6.

  2012

  Thomas J. Urban; David B. Goldstein; Paul B. Watkins

  Genetic basis of susceptibility to drug-induced liver injury: What have we learned and where do we go from here?

  Pharmacogenomics. 2012;13(7):735-738.
  0

• 7.

  2012

  Daniel L. Hertz; Christine M. Walko; Arlene S. Bridges; J. Heyward Hull; Jill Herendeen; Kristan Rollins; Paul B. Watkins; E. Claire Dees

  Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure

  British Journal of Clinical Pharmacology. 2012;74(1):197-200.
  1

• 8.

  2012

  L.N. Bell; R. Vuppalanchi; P.B. Watkins; H.L. Bonkovsky; J. Serrano; R.J. Fontana; M. Wang; J. Rochon; N. Chalasani

  Serum proteomic profiling in patients with drug-induced liver injury

  Alimentary Pharmacology and Therapeutics. 2012;35(5):600-612.
  2

• 9.

  2012

  Jeffrey L. Woodhead; Brett A. Howell; Yuching Yang; Alison H. Harrill; Harvey J. Clewell III; Melvin E. Andersen; Scott Q. Siler; Paul B. Watkins

  An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury

  Journal of Pharmacology and Experimental Therapeutics. 2012;342(2):529-540.
  1

• 10.

  2012

  A.H. Harrill; J. Roach; I. Fier; J.S. Eaddy; C.L. Kurtz; D.J. Antoine; D.M. Spencer; T.K. Kishimoto; D.S. Pisetsky; B.K. Park; et al.

  The effects of heparins on the liver: Application of mechanistic serum biomarkers in a randomized study in healthy volunteers

  Clinical Pharmacology and Therapeutics. 2012;92(2):214-220.
  2

• 11.

  2012

  Thomas J. Urban; Yufeng Shen; Andrew Stolz; Naga Chalasani; Robert J. Fontana; James Rochon; Dongliang Ge; Kevin V. Shianna; Ann K. Daly; M. Isabel Lucena; et al.

  Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs

  Pharmacogenetics and Genomics. 2012;22(11):784-795.
  1

• 12.

  2012

  Alberto Corsini; Patricia Ganey; Cynthia Ju; Neil Kaplowitz; Dominique Pessayre; Robert Roth; Paul B. Watkins; Mudher Albassam; Baolian Liu; Saray Stancic; et al.

  Current challenges and controversies in drug-induced liver injury

  Drug Safety. 2012;35(12):1099-1117.
  1

• 13.

  2012

  Alison H. Harrill; Kristina D. DeSmet; Kristina K. Wolf; Arlene S. Bridges; J. Scott Eaddy; C. Lisa Kurtz; J. Ed. Hall; Mary F. Paine; Richard R. Tidwell; Paul B. Watkins

  A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models

  Toxicological Sciences. 2012;130(2):416-426.
  0

• 14.

  2012

  Brett A. Howell; Yuching Yang; Rukmini Kumar; Jeffrey L. Woodhead; Alison H. Harrill; Harvey J. Clewell III; Melvin E. Andersen; Scott Q. Siler; Paul B. Watkins

  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsymTM: A mechanistic, mathematical model of DILI

  Journal of Pharmacokinetics and Pharmacodynamics. 2012;39(5):527-541.
  2

• 15.

  2011

  Paul B. Watkins; Mehul Desai; Scott D. Berkowitz; Gary Peters; Yves Horsmans; Dominique Larrey; Willis Maddrey

  Evaluation of drug-induced serious hepatotoxicity (eDISH): Application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery

  Drug Safety. 2011;34(3):243-252.
  8

• 16.

  2011

  Donald G. Robertson; Paul B. Watkins; Michael D. Reily

  Metabolomics in toxicology: Preclinical and clinical applications

  Toxicological Sciences. 2011;120(SUPPL.1):S146-S170.
  14

• 17.

  2011

  G.P. Aithal; P.B. Watkins; R.J. Andrade; D. Larrey; M. Molokhia; H. Takikawa; C.M. Hunt; R.A. Wilke; M. Avigan; N. Kaplowitz; et al.

  Case definition and phenotype standardization in drug-induced liver injury

  Clinical Pharmacology and Therapeutics. 2011;89(6):806-815.
  34

• 18.

  2011

  P.B. Watkins

  Drug safety sciences and the bottleneck in drug development

  Clinical Pharmacology and Therapeutics. 2011;89(6):788-790.
  9

• 19.

  2011

  M. Isabel Lucena; Mariam Molokhia; Yufeng Shen; Thomas J. Urban; Guruprasad P. Aithal; Ral J. Andrade; Christopher P. Day; Francisco Ruizcabello; Peter T. Donaldson; Camilla Stephens; et al.

  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class i and II alleles

  Gastroenterology. 2011;141(1):338-347.
  42

• 20.

  2010

  Rick D. Fannin; Mark Russo; Thomas M. O'Connell; Kevin Gerrish; Jason H. Winnike; Jeffrey Macdonald; Jack Newton; Shahid Malik; Stella O. Sieber; Joel Parker; et al.

  Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation

  Hepatology. 2010;51(1):227-236.
  24

• 21.

  2010

  Barbara A. Wetmore; Dominique J. Brees; Reetu Singh; Paul B. Watkins; Melvin E. Andersen; James Loy; Russell S. Thomas

  Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury

  Hepatology. 2010;51(6):2127-2139.
  15

• 22.

  2010

  J.H. Winnike; Z. Li; F.A. Wright; J.M. MacDonald; T.M. O'Connell; P.B. Watkins

  Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans

  Clinical Pharmacology and Therapeutics. 2010;88(1):45-51.
  40

• 23.

  2010

  Paul B Watkins

  Biomarkers for drug-induced liver injury

  Therapy. 2010;7(4):367-375.
  0

• 24.

  2010

  T.M. O'Connell; P.B. Watkins

  The application of metabonomics to predict drug-induced liver injury

  Clinical Pharmacology and Therapeutics. 2010;88(3):394-399.
  19

• 25.

  2010

  Joanna D. Stewart; Rita Horvath; Enrico Baruffini; Iliana Ferrero; Stefanie Bulst; Paul B. Watkins; Robert J. Fontana; Christopher P. Day; Patrick F. Chinnery

  Polymerase γGene POLG determines the risk of sodium valproate-induced liver toxicity

  Hepatology. 2010;52(5):1791-1796.
  23

• 26.

  2009

  Robert J. Fontana; Paul B. Watkins; Herbert L. Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon

  Drug-induced liver injury network (DILIN) prospective study: Rationale, design and conduct

  Drug Safety. 2009;32(1):55-68.
  50

• 27.

  2009

  Tong Zhou; Jeff Chou; Paul B Watkins; William K Kaufmann

  Toxicogenomics: transcription profiling for toxicology assessment.

  EXS. 2009;99:325-366.
  4

• 28.

  2009

  Paul H. Hayashi; Paul Watkins

  Progress in our understanding of severe drug-induced liver injury

  Liver Transplantation. 2009;15(7):675-676.
  1

• 29.

  2009

  Alison H. Harrill; Paul B. Watkins; Stephen Su; Pamela K. Ross; David E. Harbourt; Ioannis M. Stylianou; Gary A. Boorman; Mark W. Russo; Richard S. Sackler; Stephen C. Harris; et al.

  Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans

  Genome Research. 2009;19(9):1507-1515.
  47

• 30.

  2009

  Paul B. Watkins

  Biomarkers for the diagnosis and management of drug-induced liver injury

  Seminars in Liver Disease. 2009;29(4):393-399.
  14

• 31.

  2009

  Jason H. Winnike; Marjorie G. Busby; Paul B. Watkins; Thomas M. O'Connell

  Effects of a prolonged standardized diet on normalizing the human metabolome

  American Journal of Clinical Nutrition. 2009;90(6):1496-1501.
  11

• 32.

  2008

  Nina Isoherranen; Shana R. Ludington; Raymond C. Givens; Jatinder K. Lamba; Susan N. Pusek; E. Claire Dees; David K. Blough; Kazunori Iwanaga; Roy L. Hawke; Erin G. Schuetz; et al.

  The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: An in vitro-in vivo evaluation

  Drug Metabolism and Disposition. 2008;36(1):146-154.
  19

• 33.

  2008

  Patricia C. Chulada; Heather L. Vahdat; Richard R. Sharp; Tracy C. DeLozier; Paul B. Watkins; Susan N. Pusek; Perry J. Blackshear

  The Environmental Polymorphisms Registry: A DNA resource to study genetic susceptibility loci

  Human Genetics. 2008;123(2):207-214.
  6

• 34.

  2008

  Balasubramanian Poonkuzhali; Jatinder Lamba; Stephen Strom; Alex Sparreboom; Kenneth Thummel; Paul Watkins; Erin Schuetz

  Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms

  Drug Metabolism and Disposition. 2008;36(4):780-795.
  18

• 35.

  2008

  Mary F. Paine; Wilbur W. Widmer; Susan N. Pusek; Kimberly L. Beavers; Anne B. Criss; Jennifer Snyder; Paul B. Watkins

  Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: Studies with cyclosporine

  American Journal of Clinical Nutrition. 2008;87(4):863-871.
  22

• 36.

  2008

  Paul B. Watkins

  Drug-induced liver injury network

  American Journal of Gastroenterology. 2008;103(6):1574-1575.
  3

• 37.

  2008

  James Rochon; Petr Protiva; Leonard B. Seeff; Robert J. Fontana; Suthat Liangpunsakul; Paul B. Watkins; Timothy Davern; John G. McHutchison

  Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury

  Hepatology. 2008;48(4):1175-1183.
  51

• 38.

  2008

  Paul B. Watkins; Paul J. Seligman; John S. Pears; Mark I. Avigan; John R. Senior

  Using controlled clinical trials to learn more about acute drug-induced liver injury

  Hepatology. 2008;48(5):1680-1689.
  30

• 39.

  2008

  Naga Chalasani; Robert J. Fontana; Herbert L. Bonkovsky; Paul B. Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon

  Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States

  Gastroenterology. 2008;135(6):1924-1934.e4.
  132

• 40.

  2007

  Elaine M. Leslie; Paul B. Watkins; Richard B. Kim; Kim L. R. Brouwer

  Differential inhibition of rat and human Na⁺-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: A mechanism for species differences in hepatotoxicity

  Journal of Pharmacology and Experimental Therapeutics. 2007;321(3):1170-1178.
  30

• 41.

  2007

  Paul B. Watkins; Louise M. Dube; Karen Walton-Bowen; Christopher M. Cameron; Linda E. Kasten

  Clinical pattern of zileuton-associated liver injury: Results of a 12-month study in patients with chronic asthma

  Drug Safety. 2007;30(9):805-815.
  13

• 42.

  2007

  C. Warren Olanow; Paul B. Watkins

  Tolcapone: An efficacy and safety review (2007)

  Clinical Neuropharmacology. 2007;30(5):287-294.
  30

• 43.

  2007

  Russell A. Wilke; Debbie W. Lin; Dan M. Roden; Paul B. Watkins; David Flockhart; Issam Zineh; Kathleen M. Giacomini; Ronald M. Krauss

  Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges

  Nature Reviews Drug Discovery. 2007;6(11):904-916.
  103

• 44.

  2007

  P.R. Bushel; A.N. Heinloth; J. Li; L. Huang; J.W. Chou; G.A. Boorman; D.E. Malarkey; C.D. Houle; S.M. Ward; R.E. Wilson; et al.

  Blood gene expression signatures predict exposure levels

  Proceedings of the National Academy of Sciences of the United States of America. 2007;104(46):18211-18216.
  60

• 45.

  2006

  Yang Xu; Takanori Hashizume; Margaret C. Shuhart; Connie L. Davis; Wendel L. Nelson; Toshiyuki Sakaki; Thomas F. Kalhorn; Paul B. Watkins; Erin G. Schuetz; Kenneth E. Thummel

  Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1α,25-dihydroxyvitamin D₃: Implications for drug-induced osteomalacia

  Molecular Pharmacology. 2006;69(1):56-65.
  68

• 46.

  2006

  Paul B. Watkins; Leonard B. Seeff

  Drug-induced liver injury: Summary of a single topic clinical research conference

  Hepatology. 2006;43(3):618-631.
  83

• 47.

  2006

  Jatinder Lamba; Stephen Strom; Raman Venkataramanan; Kenneth E. Thummel; Yvonne S. Lin; Wei Liu; Cheng Cheng; Vishal Lamba; Paul B. Watkins; Erin Schuetz

  MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype

  Clinical Pharmacology and Therapeutics. 2006;79(4):325-338.
  63

• 48.

  2006

  Jatinder K. Lamba; Xin Chen; Lu-Bin Lan; Jin Woo Kim; Xin Wei Wang; Mary V. Relling; Yasuda Kazuto; Paul B. Watkins; Stephen Strom; Daxi Sun; et al.

  Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans

  Pharmacogenetics and Genomics. 2006;16(6):415-427.
  6

• 49.

  2006

  Mary F. Paine; Wilbur W. Widmer; Heather L. Hart; Susan N. Pusek; Kimberly L. Beavers; Anne B. Criss; Sherri S. Brown; Brian F. Thomas; Paul B. Watkins

  A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction

  American Journal of Clinical Nutrition. 2006;83(5):1097-1105.
  65

• 50.

  2006

  Changcheng Zhou; Mahfoud Assem; Jessica C. Tay; Paul B. Watkins; Bruce Blumberg; Erin G. Schuetz; Kenneth E. Thummel

  Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia

  Journal of Clinical Investigation. 2006;116(6):1703-1712.
  86

• 51.

  2006

  Paul B. Watkins; Neil Kaplowitz; John T. Slattery; Connie R. Colonese; Salvatore V. Colucci; Paul W. Stewart; Stephen C. Harris

  Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial

  Journal of the American Medical Association. 2006;296(1):87-93.
  220

• 52.

  2006

  Paul B. Watkins; Neil Kaplowitz; Salvatore V. Colucci; Paul W. Stewart; Stephen C. Harris

  In reply [2]

  Journal of the American Medical Association. 2006;296(23):2798-2799.
  0

• 53.

  2005

  Paul B. Watkins

  Insight into hepatotoxicity: The troglitazone experience

  Hepatology. 2005;41(2):229-230.
  14

• 54.

  2005

  Paul B. Watkins

  Idiosyncratic liver injury: Challenges and approaches

  Toxicologic Pathology. 2005;33(1):1-5.
  56

• 55.

  2005

  Mary F. Paine; Shana S. Ludington; Mei-Ling Chen; Paul W. Stewart; Shiew-Mei Huang; Paul B. Watkins

  Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?

  Drug Metabolism and Disposition. 2005;33(3):426-433.
  57

• 56.

  2005

  Mary F. Paine; Anne B. Criss; Paul B. Watkins

  Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition

  Journal of Pharmacology and Experimental Therapeutics. 2005;312(3):1151-1160.
  41

• 57.

  2005

  E. Claire Dees; Paul B. Watkins

  Role of cytochrome P450 phenotyping in cancer treatment

  Journal of Clinical Oncology. 2005;23(6):1053-1055.
  10

• 58.

  2005

  Elaine K. Gallin; Sylvie M. Le Blancq; Donald W. Landry; Dennis Ausiello; Ravi Thadhani; Karen Zier; Steven Itzkowitz; Joel Palefsky; Peggy Nopoulos; Paul B. Watkins; et al.

  Launching a new fellowship for medical students: The first years of the Doris Duke Clinical Research Fellowship Program

  Journal of Investigative Medicine. 2005;53(2):73-81.
  7

• 59.

  2005

  Evan D. Kharasch; Kenneth E. Thummel; Paul B. Watkins

  CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition

  Molecular Interventions. 2005;5(3):151-153.
  21

• 60.

  2005

  Stéphane J. Mouly; Chris Matheny; Mary F. Paine; Glenn Smith; Jatinder Lamba; Vishal Lamba; Susan N. Pusek; Erin G. Schuetz; Paul W. Stewart; Paul B. Watkins

  Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5

  Clinical Pharmacology and Therapeutics. 2005;78(6):605-618.
  65

• 61.

  2004

  Wei C. Lau; Paul A. Gurbel; Paul B. Watkins; Charlene J. Neer; Amy S. Hopp; David G.M. Carville; Kirk E. Guyer; Alan R. Tait; Eric R. Bates

  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  Circulation. 2004;109(2):166-171.
  353

• 62.

  2004

  Mark W. Russo; Paul B. Watkins

  Are Patients with Elevated Liver Tests at Increased Risk of Drug-Induced Liver Injury?

  Gastroenterology. 2004;126(5):1477-1480.
  38

• 63.

  2004

  Shefali M. Kakar; Mary F. Paine; Paul W. Stewart; Paul B. Watkins

  6′7′-Dihydroxybergamottin contributes to the grapefruit juice effect

  Clinical Pharmacology and Therapeutics. 2004;75(6):569-579.
  50

• 64.

  2004

  Mark W. Russo; Joseph A. Galanko; Roshan Shrestha; Michael W. Fried; Paul Watkins

  Liver transplantation for acute liver failure from drug induced liver injury in the United States

  Liver Transplantation. 2004;10(8):1018-1023.
  151

• 65.

  2004

  Mary F. Paine; Anne B. Criss; Paul B. Watkins

  Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties

  Drug Metabolism and Disposition. 2004;32(10):1146-1153.
  47

• 66.

  2004

  Mary F. Paine; Louis Y. Leung; Paul B. Watkins

  New insights into drug absorption: Studies with sirolimus

  Therapeutic Drug Monitoring. 2004;26(5):463-467.
  14

• 67.

  2004

  Shiew-Mei Huang; Stephen D. Hall; Paul Watkins; Lori A. Love; Cosette Serabjit-Singh; Joseph M. Betz; Freddie Ann Hoffman; Peter Honig; Paul M. Coates; Jonca Bull; et al.

  Drug interactions with herbal products and grapefruit juice: A conference report

  Clinical Pharmacology and Therapeutics. 2004;75(1):1-12.
  47

• 68.

  2004

  E.G. Schuetz; M.V. Relling; S. Kishi; W. Yang; S. Das; P. Chen; E.H. Cook; G.L. Rosner; C.H. Pui; J.G. Blanco; et al.

  PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.

  Pharmacological reviews. 2004;56(2):159.
  14

• 69.

  2004

  Stéphane J. Mouly; Mary F. Paine; Paul B. Watkins

  Contributions of CYP3A4, P-glycoprotein, and Serum Protein Binding to the Intestinal First-Pass Extraction of Saquinavir

  Journal of Pharmacology and Experimental Therapeutics. 2004;308(3):941-948.
  47

• 70.

  2003

  Raymond C. Givens; Yvonne S. Lin; Amy L. S. Dowling; Kenneth E. Thummel; Jatinder K. Lamba; Erin G. Schuetz; Paul W. Stewart; Paul B. Watkins

  CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults

  Journal of Applied Physiology. 2003;95(3):1297-1300.
  80

• 71.

  2003

  W.C. Lau; L.A. Waskell; P.B. Watkins; C.J. Neer; K. Horowitz; A.S. Hopp; A.R. Tait; D.G. Carville; K.E. Guyer; E.R. Bates

  Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction

  Revista Portuguesa de Cardiologia. 2003;22(6):871-874.
  1

• 72.

  2003

  Wei C. Lau; Lucy A. Waskell; Paul B. Watkins; Charlene J. Neer; Kevin Horowitz; Amy S. Hopp; Alan R. Tait; David G.M. Carville; Kirk E. Guyer; Eric R. Bates

  Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction

  Circulation. 2003;107(1):32-37.
  509

• 73.

  2003

  Neil Kaplowitz; James H. Lewis; Paul B. Watkins; David W. Nierenberg

  Did this drug cause my patient's hepatitis? [3] (multiple letters)

  Annals of Internal Medicine. 2003;138(2):159-160.
  3

• 74.

  2003

  Raymond C. Givens; Paul B. Watkins

  Pharmacogenetics and clinical gastroenterology

  Gastroenterology. 2003;125(1):240-248.
  17

• 75.

  2002

  Mary F. Paine; Louis Y. Leung; H.K. Lim; Kecheng Liao; Aram Oganesian; Mei-Yi Zhang; Kenneth E. Thummel; Paul B. Watkins

  Identification of a novel route of extraction of sirolimus in human small intestine: Roles of metabolism and secretion

  Journal of Pharmacology and Experimental Therapeutics. 2002;301(1):174-186.
  23

• 76.

  2002

  Jatinder K. Lamba; Yvonne S. Lin; Kenneth Thummel; Ann Daly; Paul B. Watkins; Stephen Strom; Jiong Zhang; Erin G. Schuetz

  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations

  Pharmacogenetics. 2002;12(2):121-132.
  187

• 77.

  2002

  Stéphane Mouly; Kenneth S. Lown; David Kornhauser; Jeffrey L. Joseph; William D. Fiske; Irma H. Benedek; Paul Brent Watkins

  Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

  Clinical Pharmacology and Therapeutics. 2002;72(1):1-9.
  108

• 78.

  2002

  Craig A. Jaffe; D. Kim Turgeon; Kenneth Lown; Roberta Demott-Friberg; Paul B. Watkins

  Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans

  American Journal of Physiology - Endocrinology and Metabolism. 2002;283(5 46-5):E1008-E1015.
  76

• 79.

  2002

  Mary F. Paine; David A. Wagner; Keith A. Hoffmaster; Paul B. Watkins

  Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin

  Clinical Pharmacology and Therapeutics. 2002;72(5):524-535.
  35

• 80.

  2002

  Sompon Wanwimolruk; Mary F. Paine; Susan N. Pusek; Paul B. Watkins

  Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?

  British Journal of Clinical Pharmacology. 2002;54(6):643-651.
  8

• 81.

  2001

  L.P. Rivory; P.B. Watkins; W.L. Chiou; H. Jeong; T.C. Wu; C. Ma

  Erythromycin breath test

  Clinical Pharmacology and Therapeutics. 2001;70(4):395-399.
  16

• 82.

  2001

  Phyllissa Schmiedlin-Ren; Kenneth E. Thummel; Jeannine M. Fisher; Mary F. Paine; Paul B. Watkins

  Induction of CYP3A4 by 1α,25-dihydroxyvitamin D₃ is human cell linespecific and is unlikely to involve pregnane X receptor

  Drug Metabolism and Disposition. 2001;29(11):1446-1453.
  57

• 83.

  2001

  J. Zhang; P. Kuehl; E.D. Green; J.W. Touchman; P.B. Watkins; A. Daly; S.D. Hall; P. Maurel; M. Relling; C. Brimer; et al.

  The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants

  Pharmacogenetics. 2001;11(7):555-572.
  185

• 84.

  2001

  Peter Kuehl; Jiong Zhang; Yvonne Lin; Jatinder Lamba; Mahfoud Assem; John Schuetz; Paul B. Watkins; Ann Daly; Steven A. Wrighton; Stephen D. Hall; et al.

  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  Nature Genetics. 2001;27(4):383-391.
  1074

• 85.

  2001

  Shefali Malhotra; David G Bailey; Mary F Paine; Paul B Watkins

  Seville orange juice-felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins

  Clinical Pharmacology and Therapeutics. 2001;69(1):14-23.
  111

• 86.

  2001

  Y.S. Lin; G.F. Lockwood; M.A. Graham; W.R. Brian; C.-M. Loi; M.R. Dobrinska; D.D. Shen; P.B. Watkins; G.R. Wilkinson; E.D. Kharasch; et al.

  In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

  Pharmacogenetics. 2001;11(9):781-791.
  77

• 87.

  2000

  Kenneth E. Thummel; John T. Slattery; Howard Ro; Jenny Y. Chien; Sidney D. Nelson; Kenneth E. Lown; Paul B. Watkins

  Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults

  Clinical Pharmacology and Therapeutics. 2000;67(6):591-599.
  66

• 88.

  2000

  JoAnn Hirth; Paul B. Watkins; Myla Strawderman; Anne Schott; René Bruno; Laurence H. Baker

  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

  Clinical Cancer Research. 2000;6(4):1255-1258.
  126

• 89.

  2000

  P.B. Watkins; M.T. Kinirons; D. O'Shea; R.B. Kim; A.J.J. Wood; G.R. Wilkinson

  Erythromycin breath test (multiple letters)

  Clinical Pharmacology and Therapeutics. 2000;67(5):577-578.
  5

• 90.

  2000

  Steven A. Wrighton; Erin G. Schuetz; Kenneth E. Thummel; Danny D. Shen; Kenneth R. Korzekwa; Paul B. Watkins

  The human CYP3A subfamily: Practical considerations

  Drug Metabolism Reviews. 2000;32(3-4):339-361.
  141

• 91.

  1999

  Jeannine M. Fisher; Steven A. Wrighton; Paul B. Watkins; Phyllissa Schmiedlin-Ren; Justina C. Calamia; Danny D. Shen; Kent L. Kunze; Kenneth E. Thummel

  First-pass midazolam metabolism catalyzed by 1α,25-dihydroxy vitamin D₃-modified Caco-2 cell monolayers

  Journal of Pharmacology and Experimental Therapeutics. 1999;289(2):1134-1142.
  55

• 92.

  1999

  Stephen D. Hall; Kenneth E. Thummel; Paul B. Watkins; Kenneth S. Lown; Leslie Z. Benet; Mary F. Paine; Robert R. Mayo; D. Kim Turgeon; David G. Bailey; Robert J. Fontana; et al.

  Molecular and physical mechanisms of first-pass extraction

  Drug Metabolism and Disposition. 1999;27(2):161-166.
  165

• 93.

  1999

  Mary F. Paine; Phyllissa Schmiedlin-Ren; Paul B. Watkins

  Cytochrome P-450 1A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole

  Drug Metabolism and Disposition. 1999;27(3):360-364.
  61

• 94.

  1999

  R.J. Fontana; K.S. Lown; M.F. Paine; L. Fortlage; R.M. Santella; J.S. Felton; M.G. Knize; A. Greenberg; P.B. Watkins

  Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P- glycoprotein levels in healthy volunteers

  Gastroenterology. 1999;117(1):89-98.
  74

• 95.

  1999

  Steven J. Hughes; Mark A. Morse; Christopher M. Weghorst; Hyesook Kim; Paul B. Watkins; F. Peter Guengerich; Mark B. Orringer; David G. Beer

  Cytochromes P450 are Expressed in Proliferating Cells in Barrett's Metaplasia

  Neoplasia. 1999;1(2):145-153.
  13

• 96.

  1999

  David J. Edwards; Michael E. Fitzsimmons; Erin G. Schuetz; Kazuto Yasuda; Murray P. Ducharme; Lawrence H. Warbasse; Patrick M. Woster; John D. Schuetz; Paul Watkins

  6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein

  Clinical Pharmacology and Therapeutics. 1999;65(3):237-244.
  168

• 97.

  1998

  Kenneth S. Lown; Mita Ghosh; Paul B. Watkins

  Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical

  Drug Metabolism and Disposition. 1998;26(2):185-187.
  41

• 98.

  1998

  P.B. Watkins; R.W. Whitcomb

  Hepatic dysfunction associated with troglitazone [1]

  New England Journal of Medicine. 1998;338(13):916-917.
  319

• 99.

  1998

  Robert J. Fontana; Tina M. DeVries; Thomas F. Woolf; Margaret J. Knapp; A.S. Brown; Laurence S. Kaminsky; Bing-Kuo Tang; Norman L. Foster; Richard R. Brown; Paul B. Watkins

  Caffeine based measures of CYP IA2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease

  British Journal of Clinical Pharmacology. 1998;46(3):221-228.
  17

• 100.

  1997

  Ching-Ling Cheng; David E. Smith; Peggy L. Carver; Steven R. Cox; Paul B. Watkins; Debbie S. Blake; Carol A. Kauffman; Katherine M. Meyer; Gordon L. Amidon; et al.

  Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test

  Clinical Pharmacology and Therapeutics. 1997;61(5):531-543.
  51

• 101.

  1997

  Kenneth S. Lown; Robert R. Mayo; Alan B. Leichtman; Hsiu-Ling Hsiao; D. Kim Turgeon; Phyllissa Schmiedlin-Ren; Morton B. Brown; Wensheng Guo; Stephen J. Rossi; Leslie Z. Benet; et al.

  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

  Clinical Pharmacology and Therapeutics. 1997;62(3):248-260.
  527

• 102.

  1997

  Paul B. Watkins

  The barrier function of CYP3A4 and P-glycoprotein in the small bowel

  Advanced Drug Delivery Reviews. 1997;27(2-3):161-170.
  270

• 103.

  1997

  Carlos A. Jamis-Dow; Michael L. Pearl; Paul B. Watkins; Debbie S. Blake; Raymond W. Klecker; Jerry M. Collins

  Predicting drug interactions in vivo from experiments in vitro: Human studies with paclitaxel and ketoconazole

  American Journal of Clinical Oncology: Cancer Clinical Trials. 1997;20(6):592-599.
  35

• 104.

  1997

  Phyllissa Schmiedlin-Ren; David J. Edwards; Michael E. Fitzsimmons; Kan He; Kenneth S. Lown; Patrick M. Woster; Atiqur Rahman; Kenneth E. Thummel; Jeannine M. Fisher; Paul F. Hollenberg; et al.

  Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins

  Drug Metabolism and Disposition. 1997;25(11):1228-1233.
  280

• 105.

  1997

  Phyllissa Schmiedlin-Ren; Kenneth E. Thummel; Jeannine M. Fisher; Mary F. Paine; Kenneth S. Lown; Paul B. Watkins

  Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α,25- dihydroxyvitamin D₃

  Molecular Pharmacology. 1997;51(5):741-754.
  211

• 106.

  1997

  Kenneth S. Lown; David G. Bailey; Robert J. Fontana; Srinivas K. Janardan; Constance H. Adair; Laurie A. Fortlage; Morton B. Brown; Wensheng Guo; Paul B. Watkins

  Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

  Journal of Clinical Investigation. 1997;99(10):2545-2553.
  432

• 107.

  1996

  Paul B. Watkins

  Erythromycin breath test and clinical transplantation

  Therapeutic Drug Monitoring. 1996;18(4):368-371.
  20

• 108.

  1996

  Srinivas K. Janardan; Kenneth S. Lown; Phyllissa Schmiedlin-Ren; Kenneth E. Thummel; Paul B. Watkins

  Selective expression of CYP3A5 and not CYP3A4 in human blood

  Pharmacogenetics. 1996;6(5):379-385.
  39

• 109.

  1996

  Robert J. Fontana; D. Kim Turgeon; Thomas F. Woolf; Maegaret J. Knapp; Norman L. Foster; Paul B. Watkins

  The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity

  Hepatology. 1996;23(6):1429-1435.
  21

• 110.

  1996

  Barbara D. Haehner; J. Christopher Gorski; Mark Vandenbranden; Steven A. Wrighton; Srinivas K. Janardan; Paul B. Watkins; Stephen D. Hall

  Bimodal distribution of renal cytochrome P450 3A activity in humans

  Molecular Pharmacology. 1996;50(1):52-59.
  127

• 111.

  1995

  C.A. Jaffe; D.K. Turgeon; R.D. Friber; P.B. Watkins; A.L. Barkan

  Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: Potential involvement of endogenous somatostatin - A clinical research center study

  Journal of Clinical Endocrinology and Metabolism. 1995;80(11):3321-3326.
  32

• 112.

  1995

  Kenneth S. Lown; Kenneth E. Thummel; Patrick E. Benedict; Danny D. Shen; Danielle K. Turgeon; Stanley Berent; Paul B. Watkins

  The erythromycin breath test predicts the clearance of midazolam

  Clinical Pharmacology and Therapeutics. 1995;57(1):16-24.
  103

• 113.

  1995

  K.S. Lown; J.C. Kolars; K.E. Thummel; J.L. Barnett; K.L. Kunze; S.A. Wrighton; P.B. Watkins

  Erratum: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test (Drug Metabolism and Disposition (1994) 22 (947-955))

  Drug Metabolism and Disposition. 1995;23(3):i.
  0

• 114.

  1995

  T. Inaba; D.W. Nebert; B. Burchell; P.B. Watkins; J.A. Goldstein; L. Bertilsson; G.T. Tucker

  Pharmacogenetics in clinical pharmacology and toxicology

  Canadian Journal of Physiology and Pharmacology. 1995;73(3):331-338.
  29

• 115.

  1995

  P.B. Watkins

  Cyclosporine and liver transplantation: Will the midazolam test make blood level monitoring obsolete?

  Hepatology. 1995;22(3):994-996.
  21

• 116.

  1995

  R.J. Fontana; P.B. Watkins

  Genetic predisposition to drug-induced liver disease

  Gastroenterology Clinics of North America. 1995;24(4):811-838.
  11

• 117.

  1995

  A. Lampen; U. Christians; F.P. Guengerich; P.B. Watkins; J.C. Kolars; A. Bader; A.-K. Gonschior; H. Dralle; I. Hackbarth; K.-F. Sewing

  Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability

  Drug Metabolism and Disposition. 1995;23(12):1315-1324.
  169

• 118.

  1994

  Joseph C. Kolars; Kenneth S. Lown; Phyllissa Schmiedlin-Ren; Mita Ghosh; Che Fang; Steven A. Wrighton; Robert M. Merion; Paul B. Watkins

  CYP3A gene expression in human gut epithelium

  Pharmacogenetics. 1994;4(5):247-259.
  282

• 119.

  1994

  Joseph C. Kolars; Patrick Benedict; Phyllissa Schmiedlin-Ren; Paul B. Watkins

  Aflatoxin B1-adduct formation in rat and human small bowel enterocytes

  Gastroenterology. 1994;106(2):433-439.
  23

• 120.

  1994

  Paul B. Watkins

  Noninvasive tests of CYP3A enzymes

  Pharmacogenetics. 1994;4(4):171-184.
  340

• 121.

  1994

  K.S. Lown; J.C. Kolars; K.E. Thummel; J.L. Barnett; K.L. Kunze; S.A. Wrighton; P.B. Watkins

  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test

  Drug Metabolism and Disposition. 1994;22(6):947-955.
  293

• 122.

  1994

  D. Kim Turgeon; Alan B. Leichtman; Kenneth S. Lown; Daniel P. Normolle; G. Michael Deeb; Robert M. Merion; Paul B. Watkins

  P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients

  Clinical Pharmacology and Therapeutics. 1994;56(3):253-260.
  45

• 123.

  1994

  D.K. Turgeon; A.B. Leichtman; D.S. Blake; R.L. Schmouder; K.S. Lown; T.M. Annesley; P.B. Watkins

  Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test: A prospective study in renal transplant recipients

  Transplantation. 1994;57(12):1736-1741.
  15

• 124.

  1994

  P.B. Watkins

  Tacrine and transaminases

  Alzheimer Disease and Associated Disorders. 1994;8(SUPPL. 2):S32-S38.
  2

• 125.

  1994

  Paul B. Watkins; Hyman J. Zimmerman; Margaret J. Knapp; Stephen I. Gracon; Karen W. Lewis

  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

  Journal of the American Medical Association. 1994;271(13):992-998.
  385

• 126.

  1993

  Phyllissa Schmiedlin-Ren; Patricke E. Benedict; William O. Dobbins III; Mita Ghosh; Joseph C. Kolars; Paul B. Watkins

  Cultured adult rat jejunal explants as a model for studying regulation of CYP3A

  Biochemical Pharmacology. 1993;46(5):905-918.
  18

• 127.

  1993

  P.B. Watkins; D.K. Turgeon; S.K. Guthrie; A.L. Remen; L. Grunhaus

  P450IIIA (CYP3A) activity in severely depressed patients [8]

  Journal of Clinical Psychopharmacology. 1993;13(5):366-367.
  1

• 128.

  1993

  P.B. Watkins

  Omeprazole induction of cytochrome P-450IA2: The importance of selecting the appropriate human model

  Hepatology. 1993;17(4):748-750.
  0

• 129.

  1992

  J.C. Kolars; P. Schmiedlin-Ren; J.D. Schuetz; C. Fang; P.B. Watkins

  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

  Journal of Clinical Investigation. 1992;90(5):1871-1878.
  379

• 130.

  1992

  D.K. Turgeon; D.P. Normolle; A.B. Leichtman; T.M. Annesley; D.E. Smith; P.B. Watkins

  Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients

  Clinical Pharmacology and Therapeutics. 1992;52(5):471-478.
  52

• 131.

  1992

  J.C. Kolars; P.L. Stetson; B.D. Rush; M.J. Ruwart; P. Schmiedlin-Ren; E.A. Duell; J.J. Voorhees; P.B. Watkins

  Cyclosporine metabolism by P450IIIA in rat enterocytes - Another determinant of oral bioavailability?

  Transplantation. 1992;53(3):596-602.
  64

• 132.

  1992

  J.C. Kolars; P. Schmiedlin-Ren; W.O. Dobbins III; J. Schuetz; S.A. Wrighton; P.B. Watkins

  Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia

  Gastroenterology. 1992;102(4):1186-1198.
  56

• 133.

  1992

  Kenneth Lown; Joseph Kolars; Kim Turgeon; Robert Merion; Steven A. Wrighton; Paul B. Watkins

  The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease

  Clinical Pharmacology and Therapeutics. 1992;51(3):229-238.
  81

• 134.

  1992

  C.M. Hunt; P.B. Watkins; P. Saenger; G.M. Stave; N. Barlascini; C.O. Watlington; J.T. Wright Jr.; P.S. Guzelian

  Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

  Clinical Pharmacology and Therapeutics. 1992;51(1):18-23.
  74

• 135.

  1992

  P.B. Watkins

  Drug metabolism by cytochromes P450 in the liver and small bowel

  Gastroenterology Clinics of North America. 1992;21(3):511-526.
  143

• 136.

  1992

  P.B. Watkins; D.K. Turgeon; P. Saenger; K.S. Lown; J.C. Kolars; T. Hamilton; K. Fishman; P.S. Guzelian; J.J. Voorhees

  Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity

  Clinical Pharmacology and Therapeutics. 1992;52(3):265-273.
  99

• 137.

  1991

  J.C. Kolars; W.M. Awni; R.M. Merion; P.B. Watkins

  First-pass metabolism of cyclosporin by gut

  Lancet. 1991;338(8781):1488-1490.
  271

• 138.

  1991

  S.A. Wrighton; P. Watkins

  Nonuniform distribution of cytochrome P450IA2 in liver [7]

  Gastroenterology. 1991;100(5 I):1487-1488.
  0

• 139.

  1991

  J.C. Kolars; D.K. Turgeon; P.B. Watkins

  Omeprazole and aryl hydrocarbon hydroxylases: Should we be worried?. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990;99:737-747

  Hepatology. 1991;13(1):197-199.
  2

• 140.

  1991

  R. Murphy; R. Swartz; P.B. Watkins

  Erratum: Acetaminophen toxicity (Ann Intern Med. (1990) 113 (799-800))

  Annals of Internal Medicine. 1991;114(3):253.
  0

• 141.

  1991

  Paul B. Watkins

  Antimicrosomal antibodies: What are they telling us?. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2: a specific marker for dihydralazine-induced hepatitis. J Clin Invest 1990;85:1967-1973

  Hepatology. 1991;13(2):385-387.
  2

• 142.

  1991

  Kenneth S. Lown; Paul B. Watkins

  Predicting drug interactions using cultured human hepatocytes. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606

  Hepatology. 1991;14(2):396-398.
  0

• 143.

  1991

  P.B. Watkins

  Breath tests as noninvasive assays of P450s

  Methods in Enzymology. 1991;206:517-522.
  14

• 144.

  1990

  R.E. Grier; G.S. Heard; P. Watkins; B. Wolf

  Low biotinidase activities in the sera of patients with impaired liver function: evidence that the liver is the source of serum biotinidase

  Clinica Chimica Acta. 1990;186(3):397-400.
  16

• 145.

  1990

  R. Murphy; R. Swartz; P.B. Watkins

  Severe acetaminophen toxicity in a patient receiving isoniazid

  Annals of Internal Medicine. 1990;113(10):799-800.
  41

• 146.

  1990

  M.R. Lucey; J.C. Kolars; R.M. Merion; D.A. Campbell; M. Aldrich; P.B. Watkins

  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA

  Lancet. 1990;335(8680):11-15.
  71

• 147.

  1990

  P.B. Watkins; T.A. Hamilton; T.M. Annesley; C.N. Ellis; J.C. Kolars; J.J. Voorhees

  The erythromycin breath test as a predictor of cyclosporine blood levels

  Clinical Pharmacology and Therapeutics. 1990;48(2):120-129.
  61

• 148.

  1990

  Paul B. Watkins; Scott A. Murray; Paul E. Thomas; Steven A. Wrighton

  Distribution of cytochromes P-450, cytochrome b₅, and nadph-cytochrome P-450 reductase in an entire human liver

  Biochemical Pharmacology. 1990;39(3):471-476.
  15

• 149.

  1990

  J.C. Kolars; S.A. Murray; K.M. Peters; P.B. Watkins

  Differential regulation of liver P-450III cytochromes in choline-deficient rats: Implications for the erythromycin breath test as a parameter of liver function

  Hepatology. 1990;12(6):1371-1378.
  5

• 150.

  1990

  P.B. Watkins

  The cytochromes P-450

  Gastroenterology International. 1990;3(4):184-188.
  3

• 151.

  1990

  P.B. Watkins

  The role of cytochromes P-450 in cyclosporine metabolism

  Journal of the American Academy of Dermatology. 1990;23(6 II SUPPL.):1301-1311.
  37

• 152.

  1990

  P.B. Watkins

  Role of cytochromes P450 in drug metabolism and hepatotoxicity

  Seminars in Liver Disease. 1990;10(4):235-250.
  77

• 153.

  1989

  S.A. Wrighton; B.J. Ring; P.B. Watkins; M. Vandenbranden

  Identification of a polymorphically expressed member of the human cytochrome P-450III family

  Molecular Pharmacology. 1989;36(1):97-105.
  152

• 154.

  1989

  P.B. Watkins; S.A. Murray; L.G. Winkelman; D.M. Heuman; S.A. Wrighton; P.S. Guzelian

  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients

  Journal of Clinical Investigation. 1989;83(2):688-697.
  262

• 155.

  1988

  P.B. Watkins; R. Schade; A.S. Mills; R.L. Carithers Jr.; D.H. Van Thiel

  Fatal hepatic necrosis associated with parenteral gold therapy

  Digestive Diseases and Sciences. 1988;33(8):1025-1029.
  7

• 156.

  1987

  S.A. Wrighton; P.E. Thomas; P. Willis; S.L. Maines; P.B. Watkins; W. Levin; P.S. Guzelian

  Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats

  Journal of Clinical Investigation. 1987;80(4):1017-1022.
  17

• 157.

  1987

  P.B. Watkins; S.A. Wrighton; E.G. Schuetz; D.T. Molowa; P.S. Guzelian

  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man

  Journal of Clinical Investigation. 1987;80(4):1029-1036.
  308

• 158.

  1986

  E.G. Schuetz; G.A. Hazelton; J. Hall; P.B. Watkins; C.D. Klaassen; P.S. Guzelian

  Induction of digitoxigenin monodigitoxoside UDP-glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450(p) in primary monolayer cultures of adult rat hepatocytes and in human liver

  Journal of Biological Chemistry. 1986;261(18):8270-8275.
  26

• 159.

  1986

  Steven A. Wrighton; Paul E. Thomas; David T. Molowa; Mitsuru Haniu; John E. Shively; Sarah L. Maines; Paul B. Watkins; George Parker; Gerald Mendez-Picon; Wayne Levin; et al.

  Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase

  Biochemistry®. 1986;25(22):6731-6735.
  51

• 160.

  1986

  P.B. Watkins; S.A. Wrighton; E.G. Schuetz; P. Maurel; P.S. Guzelian

  Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture

  Journal of Biological Chemistry. 1986;261(14):6264-6271.
  80

• 161.

  1986

  D.T. Molowa; E.G. Schuetz; S.A. Wrighton; P.B. Watkins; P. Kremers; G. Mendez-Picon; G.A. Parker; P.S. Guzelian

  Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver

  Proceedings of the National Academy of Sciences of the United States of America. 1986;83(14):5311-5315.
  53

• 162.

  1985

  P.B. Watkins; S.A. Wrighton; P. Maurel; E.G. Schuetz; G. Mendez-Picon; G.A. Parker; P.S. Guzelian

  Identification of an inducible form of cytochrome P-450 in human liver

  Proceedings of the National Academy of Sciences of the United States of America. 1985;82(18):6310-6314.
  157

• 163.

  1985

  Steven A. Wrighton; Patrick Maurel; Erin G. Schuetz; Paul B. Watkins; Beverly Young; Philip S. Guzelian

  Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450_p

  Biochemistry. 1985;24(9):2171-2178.
  131

• 164.

  1985

  S.A. Wrighton; E.G. Schuetz; P.B. Watkins; P. Maurel; J. Barwick; B.S. Bailey; H.T. Hartle; B. Young; P. Guzelian

  Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat

  Molecular Pharmacology. 1985;28(3):312-321.
  95

• 165.

  1984

  P.B. Watkins; E. Schuetz; S. Wrighton

  Degradation of cytochrome P-450 (DEX) is inhibited by troleandomycin in primary monolayer cultures of adult rat hepatocytes

  Federation Proceedings. 1984;43(6):no. 335.
  0